China's scientists outpace US biotech, AI draws capital
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Biotech VCs have long followed a recipe that pairs US university lab research with veteran pharma executives and tens of millions of dollars.
- The traditional model has generated scores of new medicines, successful companies, and financial returns for VC firms and investors.
- The industry is now being disrupted after the Covid‑era rally and subsequent decline.
- Chinese scientists are conducting innovative research faster and at lower costs than their US counterparts.
- Investors in the United States and elsewhere are being drawn to AI, shifting attention and dollars away from biotech.
Why it matters: Chinese researchers and AI firms gain funding as investors redirect dollars away from biotech, while US venture capitalists risk reduced deal flow and slower progress on new medicines. The shift could reshape capital allocation, favoring rapid, low‑cost AI‑driven innovation over traditional, costly biotech pipelines.
Ask SkimNews
